Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FT-003 · 1 trial · 1 indication
Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)
| Arm | Type | Description |
|---|---|---|
| FT003 Dose 1 | EXPERIMENTAL | Low dose of FT-003 |
| FT003 Dose 2 | EXPERIMENTAL | Mid dose of FT-003 |
| FT003 Dose 3 | EXPERIMENTAL | High dose of FT-003 |
| Name | Type | Description |
|---|---|---|
| FT-003 | GENETIC | Administration via intraocular injection |
Inclusion Criteria: * Subjects that are willing and able to follow study procedures; * Female or male patients ≥18 years old at the time of signing the ICF; * Clinically diagnosed with CI-DME * HbA1c≤10% * The best corrected visual acuity (BCVA) of the studied eye is ≤ 73 letters Exclusion Criteri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
FT-003 is an investigational gene therapy being developed for the treatment of diabetic macular edema, a condition that causes vision loss in people with diabetes. It is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
FT-003 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is conducting clinical research on this gene therapy candidate for diabetic macular edema.
FT-003 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The ongoing Phase 1 trial is actively recruiting participants to evaluate the therapy.
FT-003 is being studied in a Phase 1 clinical trial registered as NCT05916391, titled 'Gene Therapy for Diabetic Macular Edema.' This trial is recruiting 18 participants in China and is open to adults aged 18 years and older of all sexes.
FT-003 is a gene therapy designed to treat diabetic macular edema. While the specific molecular target has not been disclosed, gene therapies typically work by delivering genetic material to cells to produce a therapeutic protein or correct a genetic defect. The exact mechanism of action for FT-003 is not publicly detailed.